Last reviewed · How we verify

Hydrocortisone/ Placebo and Propranolol

University of Dundee · FDA-approved active Small molecule

Hydrocortisone/ Placebo and Propranolol is a Glucocorticoid + Beta-blocker combination Small molecule drug developed by University of Dundee. It is currently FDA-approved for Acute myocardial infarction or acute coronary syndrome (investigational combination).

This combination uses hydrocortisone (a glucocorticoid) and propranolol (a beta-blocker) to suppress inflammatory and adrenergic responses, with placebo control to assess efficacy.

This combination uses hydrocortisone (a glucocorticoid) and propranolol (a beta-blocker) to suppress inflammatory and adrenergic responses, with placebo control to assess efficacy. Used for Acute myocardial infarction or acute coronary syndrome (investigational combination).

At a glance

Generic nameHydrocortisone/ Placebo and Propranolol
SponsorUniversity of Dundee
Drug classGlucocorticoid + Beta-blocker combination
TargetGlucocorticoid receptor; Beta-1 and Beta-2 adrenergic receptors
ModalitySmall molecule
Therapeutic areaCardiovascular / Endocrinology
PhaseFDA-approved

Mechanism of action

Hydrocortisone reduces inflammation and immune activation by binding glucocorticoid receptors, while propranolol blocks beta-adrenergic signaling to reduce heart rate and blood pressure. The placebo arm allows for controlled assessment of the active agents' contribution to clinical outcomes in the studied condition.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hydrocortisone/ Placebo and Propranolol

What is Hydrocortisone/ Placebo and Propranolol?

Hydrocortisone/ Placebo and Propranolol is a Glucocorticoid + Beta-blocker combination drug developed by University of Dundee, indicated for Acute myocardial infarction or acute coronary syndrome (investigational combination).

How does Hydrocortisone/ Placebo and Propranolol work?

This combination uses hydrocortisone (a glucocorticoid) and propranolol (a beta-blocker) to suppress inflammatory and adrenergic responses, with placebo control to assess efficacy.

What is Hydrocortisone/ Placebo and Propranolol used for?

Hydrocortisone/ Placebo and Propranolol is indicated for Acute myocardial infarction or acute coronary syndrome (investigational combination).

Who makes Hydrocortisone/ Placebo and Propranolol?

Hydrocortisone/ Placebo and Propranolol is developed and marketed by University of Dundee (see full University of Dundee pipeline at /company/university-of-dundee).

What drug class is Hydrocortisone/ Placebo and Propranolol in?

Hydrocortisone/ Placebo and Propranolol belongs to the Glucocorticoid + Beta-blocker combination class. See all Glucocorticoid + Beta-blocker combination drugs at /class/glucocorticoid-beta-blocker-combination.

What development phase is Hydrocortisone/ Placebo and Propranolol in?

Hydrocortisone/ Placebo and Propranolol is FDA-approved (marketed).

What are the side effects of Hydrocortisone/ Placebo and Propranolol?

Common side effects of Hydrocortisone/ Placebo and Propranolol include Hypoglycemia, Bradycardia, Fatigue, Hyperglycemia, Infection risk (from immunosuppression).

What does Hydrocortisone/ Placebo and Propranolol target?

Hydrocortisone/ Placebo and Propranolol targets Glucocorticoid receptor; Beta-1 and Beta-2 adrenergic receptors and is a Glucocorticoid + Beta-blocker combination.

Related